Literature DB >> 26831202

Hypersensitivity pneumonitis and antigen identification--An alternate approach.

M L Millerick-May1, M H Mulks2, J Gerlach3, K R Flaherty4, S L Schmidt5, F J Martinez4, R M LeVeque2, K D Rosenman3.   

Abstract

OBJECTIVES: Identification of the causal antigen for patients with hypersensitivity pneumonitis (HP) is challenging in a standard clinical setting. The purpose of this pilot study was to determine whether it was possible to evaluate the home/workplace of patients, and identify the causal antigen.
METHODS: Using a case-control study design we compared the presence of antibody to antigen collected in the environment of individuals with HP and controls consisting of family members/co-workers. Based on patient interviews, homes/workplaces were evaluated and suspected sources of antigen collected for use in immunoassays.
RESULTS: Nineteen individuals with HP participated with 15 classified as having fibrotic disease. Up to 54 bulk samples were collected from each patient's environment, with multiple isolates (antigens) cultured from each. Of the seven individuals who tested positive to one or more environmental samples, three had a positive response to more than 1 antigen from the environmental sample (range 1-9). Twelve individuals tested positive to antigen(s) on a standard panel, with only one overlapping with the antigen from the home/workplace sample. A significant association existed between results of interviews/site evaluations, and ability to collect antigen eliciting a positive response (p < 0.001).
CONCLUSION: Antigen identification was successful for patients with 'active' disease. Antigens for which patients test positive on standard panels may not be present in their environment. One benefit to patient-centered testing is the ability to develop recommendations specific to their environment. As most individuals tested positive for >1 antigen, further investigation is warranted to determine the actual antigen responsible for disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antigen; Hypersensitivity; Occupational lung disease; Pulmonary disease

Mesh:

Substances:

Year:  2015        PMID: 26831202     DOI: 10.1016/j.rmed.2015.09.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  14 in total

Review 1.  Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go.

Authors:  Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

2.  Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey.

Authors:  Julie Morisset; Kerri A Johannson; Kirk D Jones; Paul J Wolters; Harold R Collard; Simon L F Walsh; Brett Ley
Journal:  Am J Respir Crit Care Med       Date:  2017-11-27       Impact factor: 21.405

3.  Reply to Fernández Pérez: Diagnostic Decision-Making in Hypersensitivity Pneumonitis: Toward a Consensus Statement.

Authors:  Margaret L Salisbury; Jeffrey L Myers; Elizabeth A Belloli; Ella A Kazerooni; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2018-06-15       Impact factor: 21.405

Review 4.  The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.

Authors:  Fernando J Martinez; Alison Chisholm; Harold R Collard; Kevin R Flaherty; Jeffrey Myers; Ganesh Raghu; Simon L F Walsh; Eric S White; Luca Richeldi
Journal:  Lancet Respir Med       Date:  2016-12-06       Impact factor: 30.700

5.  Spectrum of childhood interstitial and diffuse lung diseases at a tertiary hospital in Egypt.

Authors:  Salma G Abdelhady; Eman M Fouda; Malak A Shaheen; Faten A Ghazal; Ahmed M Mostafa; Ahmed M Osman; Andrew G Nicholson; Heba M Hamza
Journal:  ERJ Open Res       Date:  2021-06-07

Review 6.  Identification and Remediation of Environmental Exposures in Patients With Interstitial Lung Disease: Evidence Review and Practical Considerations.

Authors:  Carla R Copeland; Bridget F Collins; Margaret L Salisbury
Journal:  Chest       Date:  2021-02-18       Impact factor: 10.262

Review 7.  Chronic hypersensitivity pneumonitis.

Authors:  Carlos Ac Pereira; Andréa Gimenez; Lilian Kuranishi; Karin Storrer
Journal:  J Asthma Allergy       Date:  2016-09-21

Review 8.  The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement.

Authors:  Paul D Blanc; Isabella Annesi-Maesano; John R Balmes; Kristin J Cummings; David Fishwick; David Miedinger; Nicola Murgia; Rajen N Naidoo; Carl J Reynolds; Torben Sigsgaard; Kjell Torén; Denis Vinnikov; Carrie A Redlich
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

9.  Identifying causation in hypersensitivity pneumonitis: a British perspective.

Authors:  Christopher Michael Barber; P Sherwood Burge; Jo R Feary; Helen Parfrey; Elizabeth A Renzoni; Lisa G Spencer; Gareth I Walters; Ruth E Wiggans
Journal:  BMJ Open Respir Res       Date:  2019-12-03

10.  Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Christopher J Ryerson; Jeffrey L Myers; Michael Kreuter; Martina Vasakova; Elena Bargagli; Jonathan H Chung; Bridget F Collins; Elisabeth Bendstrup; Hassan A Chami; Abigail T Chua; Tamera J Corte; Jean-Charles Dalphin; Sonye K Danoff; Javier Diaz-Mendoza; Abhijit Duggal; Ryoko Egashira; Thomas Ewing; Mridu Gulati; Yoshikazu Inoue; Alex R Jenkins; Kerri A Johannson; Takeshi Johkoh; Maximiliano Tamae-Kakazu; Masanori Kitaichi; Shandra L Knight; Dirk Koschel; David J Lederer; Yolanda Mageto; Lisa A Maier; Carlos Matiz; Ferran Morell; Andrew G Nicholson; Setu Patolia; Carlos A Pereira; Elisabetta A Renzoni; Margaret L Salisbury; Moises Selman; Simon L F Walsh; Wim A Wuyts; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 30.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.